Mobile

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin with 5 FU/LV plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-003844-31

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare Arm A versus Arm B in terms of PFS measured from the time of randomization after completing 6 cycles of first-line therapy for metastatic CRC: • Arm A: 5-FU/LV plus bevacizumab in combination with enzastaurin • Arm B: 5-FU/LV plus bevacizumab in combination with placebo.

Critère d'inclusion

  • Locally-advanced or Metastatic Colorectal Cancer

Liens